Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 55
Filter
Add more filters










Publication year range
1.
Fundam Clin Pharmacol ; 15(2): 75-84, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11468017

ABSTRACT

Although the cytochrome P450 (CYP) system ranks first in terms of catalytic versatility and the wide range of xenobiotics it detoxifies or activates to reactive intermediates, the contribution of amine oxidases and in particular of monoamine oxidases (MAOs) to the metabolism of xenobiotics is far from negligible but has been largely neglected. In this review on the involvement of amine oxidases in the metabolism of xenobiotics, the major characteristics reported for the CYP system (protein, reaction, tissue distribution, subcellular localisation, substrates, inhibitors, inducers, genetic polymorphism, impact of different physiopathological conditions on the activity, turnover) will be compared, whenever possible, with the corresponding characteristics of amine oxidases (MAOs in particular). The knowledge of the involvement of MAO-A, -B or both in the metabolism of a drug allows us to predict interactions with selective or non-selective MAO inhibitors (e.g. the metabolism of a drug deaminated by both forms of MAO is not necessarily inhibited in vivo by a selective MAO-A or -B inhibitor). If a drug is metabolized by MAOs, competitive interactions can occur with other drugs that are MAO substrates, e.g. with beta-adrenoceptor agonists and antagonists, prodrugs of dopamine, serotonin 5-HT1-receptor agonists as well as with primaquine, flurazepam and citalopram. Moreover, the knowledge of the involvement of MAOs in the metabolism of a drug may suggest possible, although not obligatory, interactions with tyramine-containing food or drink, with over the counter medicines sold to relieve the symptoms of coughs and colds (generally containing the indirectly-acting sympathomimetic amine phenylpropanolamine) or with phenylephrine-containing preparations. Finally, biotransformation by amine oxidases, as by CYP, does not always lead to detoxication but can produce toxic compounds.


Subject(s)
Monoamine Oxidase/metabolism , Xenobiotics/metabolism , Animals , Biotransformation , Cytochrome P-450 Enzyme System/metabolism , Flavin-Adenine Dinucleotide/metabolism , Humans , Liver/enzymology , Mitochondria/enzymology , Monoamine Oxidase/chemistry , Monoamine Oxidase/genetics , Monoamine Oxidase Inhibitors/pharmacology , Oxidoreductases Acting on CH-NH Group Donors/metabolism , Polyamine Oxidase
2.
Eur J Clin Pharmacol ; 57(8): 571-82, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11758635

ABSTRACT

The main goal of the present study was to investigate the absorption and disposition of levocetirizine dihydrochloride, the R enantiomer of cetirizine dihydrochloride, following a single oral administration (5 mg) of the 14C-labelled compound in healthy volunteers. Configurational stability was also investigated. Levocetirizine was rapidly and extensively absorbed: 85.4% and 12.9% of the radioactive dose were recovered 168 h post-dose in urine and faeces, respectively. Levocetirizine and/or its metabolites were not, or only very poorly, associated with blood cells, as the blood-to-plasma ratio was 0.51 to 0.68. The mean apparent volume of distribution (Vz/F) was 26.9 1 (0.3 l/kg) indicating that the distribution of levocetirizine is restrictive. The protein binding of radiolabelled levocetirizine was 96.1% l h after administration. In vitro, at concentrations ranging from 0.2 microg/ml to 1 microg/ml, the protein binding was 94.8% to 95.0%. Levocetirizine is very poorly metabolised. The cumulative 48-h excretion as parent compound accounted for 85.8% of the oral dose, equivalent to 95% of the total radioactivity excreted at this time. At least 13 minor metabolites were detected in urine and represented 2.4% of the dose at 48 h. The metabolic pathways involved in levocetirizine metabolism are oxidation (hydroxylation, O-dealkylation, N-oxidation and N-dealkylation), glucuroconjugation, taurine conjugation and glutathione conjugation with formation of the mercapturic acids. There was no evidence of chiral inversion of levocetirizine in humans. This result is consistent with that obtained in preclinical studies.


Subject(s)
Cetirizine/pharmacokinetics , Histamine H1 Antagonists/pharmacokinetics , Adult , Carbon Radioisotopes , Cetirizine/adverse effects , Cetirizine/chemistry , Chromatography, High Pressure Liquid , Histamine H1 Antagonists/adverse effects , Histamine H1 Antagonists/chemistry , Humans , Male , Middle Aged , Molecular Structure , Phenotype , Spectrometry, Mass, Electrospray Ionization , Stereoisomerism
3.
Fundam Clin Pharmacol ; 14(4): 301-19, 2000.
Article in English | MEDLINE | ID: mdl-11030437

ABSTRACT

The aim of this paper is to review a number of new antiepileptic agents (i.e. felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin and zonisamide) for their inducing and/or inhibitory properties in humans, mainly considering the interactions where they are involved as the cause rather than the object of such interactions. Two aspects have been particularly taken into account: the changes or absence of changes in plasma/serum concentrations of concomitant drugs and the direct or indirect evidence of induction, inhibition or lack of effect on the six major human hepatic CYP isozymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4), as well as on other CYP isozymes or enzyme systems. Felbamate clearly affects the pharmacokinetics of a number of drugs, generally increasing but also decreasing their concentrations. It induces enzymes such as CYP3A4 and inhibits enzymes such as CYP2C19 and those of the beta-oxidation pathway. Topiramate is not devoid of potential interaction properties: it decreases the plasma concentrations of ethinylestradiol, induces CYP3A4 and inhibits CYP2C19. For oxcarbazepine, no inhibitory, only inductive effects have been observed thus far. Felbamate. topiramate and oxcarbazepine may induce the metabolism of steroidal oral contraceptives. In this respect, tiagabine has been studied at a rather low dose. Pharmacodynamic or pharmacokinetic interaction seems to exist between lamotrigine and carbamazepine. Lamotrigine appears to be a weak inducer of UGTs, whereas induction of CYP3A4 seems improbable as the compound does not change the concentrations of oral contraceptives or the urinary excretion of 6beta-hydroxycortisol. Zonisamide has very peculiar pharmacokinetics and an extensive metabolism. Additional information on its enzyme inducing or inhibiting properties would be necessary, as data so far collected on its effect on the pharmacokinetics of other drugs are conflicting. Gabapentin, vigabatrin and in particular levetiracetam appear to be devoid of significant enzyme inducing or inhibiting properties.


Subject(s)
Anticonvulsants/adverse effects , Enzyme Inhibitors/adverse effects , Epilepsy/drug therapy , Anticonvulsants/pharmacokinetics , Anticonvulsants/pharmacology , Clinical Trials as Topic , Drug Interactions , Enzyme Induction , Enzyme Inhibitors/pharmacokinetics , Enzyme Inhibitors/pharmacology , Epilepsy/enzymology , Epilepsy/metabolism , Humans
4.
Pharmacol Res ; 41(2): 239-48, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10623492

ABSTRACT

Plasma pharmacokinetics, excretion balance and urinary metabolites of methoxymorpholino doxorubicin (MMDX) were investigated in male and female rats and in female dogs after i.v. administration of the(14)C-labelled drug. The mean total recovery of radioactivity in 96 h (urine plus faeces) was approximately 74 and 60% dose in male and female rats, respectively, while in female dogs approximately 72% dose was recovered in 336 h. Most of the radioactivity was present in faeces, with the urinary elimination accounting for only 3-4% dose in rats and dogs. These data suggest that biliary excretion is an important route of elimination of MMDX and/or its metabolites in both species. No differences were observed in the urinary metabolic profile of male and female rats. Two main peaks were present in radiochromatograms of urine from rats and dogs, i.e. MMDX and its 13-dihydro metabolite (MMDX-ol), accounting for approximately 25 and 20% of total radioactivity in 0-24-h urine in rats and 30 and 36% in dogs. The MMDX-ol/MMDX ratio in dog urine was higher than that observed in rat urine. No aglycones were detected in the urine samples from either species. In the rat, the plasma concentration-time profile suggested that the disposition of MMDX, MMDX-ol and total radioactivity is not sex-dependent. MMDX was the major species present in the systemic circulation; its AUC (0-96 h) accounted for 70% of total plasma radioactivity with the sum of AUC (MMDX) plus AUC (MMDX-ol) accounting for 77% of total radioactivity. In the dog, the sum of AUC (MMDX) plus AUC (MMDX-ol) amounted to 8% of radioactivity AUC(0-t(z) indicating that an important proportion of other(s) unknown metabolite(s) is present in dog plasma. Plasma levels of MMDX-ol in the rat were approximately 10-fold lower than those of the parent compound, whereas they were three times higher than those of MMDX in the dog. These data show that the reduction of the 13-keto group of MMDX is species-dependent, and occurs preferentially in the dog compared to the rat.


Subject(s)
Antineoplastic Agents/pharmacokinetics , Doxorubicin/analogs & derivatives , Animals , Antineoplastic Agents/blood , Antineoplastic Agents/urine , Biotransformation , Dogs , Doxorubicin/blood , Doxorubicin/pharmacokinetics , Doxorubicin/urine , Female , Injections, Intravenous , Male , Oxidation-Reduction , Rats , Sex Characteristics , Species Specificity , Tissue Distribution
5.
Pharmacol Res ; 40(4): 351-6, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10527648

ABSTRACT

The effect of repeated administration of rifabutin on the pharmacokinetics and metabolism of ethambutol was evaluated in ten healthy volunteers. The subjects received a single oral administration of 1200 mg ethambutol on days 1 and 10 and a single daily oral dose of 300 mg rifabutin from days 3 to 9. No statistically significant difference was found in plasma pharmacokinetics (C(max), t(max), AUC, half-life and MRT) and in the renal clearance, whereas a significant decrease in the amount of unchanged ethambutol excreted in urine was observed. The decrease observed in ethambutol urinary excretion may be accounted for by taking into consideration the variability of the urinary excretion of ethambutol reported in the literature. However, a slight, likely not clinically relevant, induction or activation of kidney alcohol and/or aldehyde dehydrogenase isoenzymes by rifabutin cannot be ruled out at present. Evidence exists in the present study for autoinduction of rifabutin metabolism; this is shown by the lower plasma concentrations obtained 24 h after the seventh dose as compared to the theoretical concentrations.


Subject(s)
Antibiotics, Antitubercular/pharmacology , Antitubercular Agents/pharmacokinetics , Ethambutol/pharmacokinetics , Rifabutin/pharmacology , Adult , Antibiotics, Antitubercular/blood , Antitubercular Agents/blood , Antitubercular Agents/urine , Drug Therapy, Combination , Ethambutol/blood , Ethambutol/urine , Humans , Male , Middle Aged , Rifabutin/blood
6.
Ann Neurol ; 43(2): 212-6, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9485062

ABSTRACT

Recently, an endogenous catechol isoquinoline, 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline [N-methyl(R)salsolinol], was proved to be a neurotoxin specific for dopamine neurons by in vivo and in vitro experiments. This N-methyl(R)salsolinol was found to increase significantly in the cerebrospinal fluid of untreated parkinsonian patients, suggesting its possible involvement in the pathogenesis of Parkinson's disease. To clarify the mechanism of the increase, the activity of enzymes related to the metabolism of the neurotoxin was examined in lymphocytes prepared from parkinsonian patients and controls. In patients with Parkinson's disease, the activity of a neutral N-methyltransferase, measured by using (R)salsolinol as a substrate, was found to increase significantly (100.2 +/- 81.8 pmol/min/mg of protein) in comparison with that in controls (18.9 +/- 15.0 pmol/min/mg of protein). The distribution of the activity was bimodal in the parkinsonian patients, whereas it was singular in controls. The activity of other related enzymes, an alkaline N-methyltransferase and N-methyl(R)salsolinol oxidase, in parkinsonian lymphocytes was the same as in controls. Increase of the neutral N-methyltransferase may be an endogenous factor in the pathogenesis of Parkinson's disease.


Subject(s)
Isoquinolines/metabolism , Lymphocytes/enzymology , Methyltransferases/blood , Parkinson Disease/enzymology , Aged , Aged, 80 and over , Analysis of Variance , Female , Humans , Hydrogen-Ion Concentration , In Vitro Techniques , Male , Middle Aged , Statistics, Nonparametric , Substrate Specificity
7.
Neurosci Lett ; 232(3): 147-50, 1997 Sep 05.
Article in English | MEDLINE | ID: mdl-9310301

ABSTRACT

In retinoic acid-differentiated SH-SY5Y cells an endogenous neurotoxin N-methyl(R)salsolinol induced apoptotic cell death. Using a single cell gel electrophoresis (comet) assay, DNA damage was quantitatively measured, and it was found to depend on the concentration of N-methyl(R)salsolinol and the incubation time up to 6 h. The differentiated cells were more sensitive to N-methyl(R)salsolinol than the undifferentiated cells. Radical scavengers protected the cells from DNA damage, indicating oxidative stress is involved in the apoptotic cell process. These results suggest that apoptosis induced by endogenous neurotoxins might be the mechanism of the cell death of dopamine neurons in Parkinson's disease.


Subject(s)
Apoptosis/drug effects , Cell Count/drug effects , Isoquinolines/pharmacology , Neuroblastoma/metabolism , Neurotoxins/pharmacology , Cells, Cultured , Dopamine/metabolism , Dose-Response Relationship, Drug , Humans
8.
Eur Neuropsychopharmacol ; 7 Suppl 1: S23-35; discussion S71-3, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9169308

ABSTRACT

The pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor, in humans and animal models are reviewed here. Reboxetine has potent antidepressant activity, low affinity for alpha-adrenergic and muscarinic receptors and low toxicity in animals. It is a mixture of (R,R) and (S,S) enantiomer, the latter being more potent but no qualitative differences in pharmacodynamic properties are observed between the two. Humans rapidly absorb reboxetine (tmax about 2 h) with a terminal half-life of elimination (t1/2) of 13 h, allowing twice-daily administration. Animal models also rapidly absorb reboxetine (tmax 0.5-2 h) but t1/2 was 1-2 h. Food does not affect bioavailability. There were no major inter-species differences in the metabolic profile of reboxetine. Elimination is principally renal in humans and monkeys. Reboxetine has linear pharmacokinetics in young, healthy males for single doses of 1-5 mg and in elderly, female depressed patients (up to 4 mg b.i.d.). Multiple dosing, gender or liver insufficiency had no significant effects on the pharmacokinetics. Elderly (particularly frail elderly) patients and patients with severe renal impairment may need dose reduction. Reboxetine shows no clinically relevant interaction with lorazepam and has no inhibitory effects on the major enzymes involved in drug metabolism. It may be possible to use reboxetine in combination with monoamine oxidase inhibitors as it has no inhibitory effect on this enzyme; in addition, it may protect patients against tyramine-induced reactions. In conclusion, reboxetine seems to be an antidepressant with negligible interference with the pharmacokinetics of other drugs thus fewer drug-drug interactions are expected.


Subject(s)
Adrenergic Uptake Inhibitors/pharmacokinetics , Antidepressive Agents/pharmacokinetics , Morpholines/pharmacokinetics , Age Factors , Animals , Area Under Curve , Biological Availability , Brain/metabolism , Food-Drug Interactions , Humans , Kidney Diseases/metabolism , Liver/drug effects , Liver/enzymology , Liver Diseases/metabolism , Morpholines/urine , Reboxetine , Stereoisomerism
9.
Br J Clin Pharmacol ; 42(6): 707-11, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8971425

ABSTRACT

1. Nicergoline, an ergot derivative previously used as a vasodilator, has gained a new indication in treating the symptoms of senile dementia. 2. Nicergoline is rapidly hydrolysed to an alcohol derivative, 1-methyl-10-alpha-methoxy-9,10-dihydrolysergol (MMDL), which is further N-demethylated to form 10-alpha-methoxy-9,10-dihydrolysergol (MDL). A few individuals display aberrant metabolism of this drug, as shown by their diminished capacity to form the MDL metabolite. The aim of this study was to determine whether defective nicergoline metabolism is associated with the debrisoquine and/or the S-mephenytoin hydroxylation polymorphisms. 3. After a single, oral 30 mg dose of nicergoline, the plasma concentrations of its two metabolites were studied in 15 subjects, divided into three groups with respect to their debrisoquine and S-mephenytoin hydroxylation phenotypes. 4. The pharmacokinetic parameters of MMDL and MDL were similar in the ten subjects who were extensive metabolisers of debrisoquine (five of whom were poor metabolisers of S-mephenytoin) (mean MMDL Cmax 59 nmol l-1 and AUC (0, th) 144 nmol l-1h, mean MDL Cmax 183 nmol l-1 and AUC 2627 nmol l-1h) but were markedly different from the five subjects who were poor metabolisers of debrisoquine (mean MMDL Cmax 356 nmol l-1 and AUC 10512 nmol l-1h, MDL concentrations below limit of quantitation). 5. We conclude that the formation of MDL from MMDL in the metabolism of nicergoline is catalysed to a major extent by CYP2D6 and that the observed interindividual variation in the metabolic pattern of the drug is related to the debrisoquine hydroxylation polymorphism.


Subject(s)
Aryl Hydrocarbon Hydroxylases , Cytochrome P-450 CYP2D6/metabolism , Cytochrome P-450 Enzyme System/metabolism , Mixed Function Oxygenases/metabolism , Nicergoline/metabolism , Vasodilator Agents/metabolism , Adult , Area Under Curve , Biotransformation , Blood Pressure/drug effects , Chromatography, High Pressure Liquid , Cytochrome P-450 CYP2C19 , Debrisoquin/metabolism , Female , Half-Life , Heart Rate/drug effects , Humans , Male , Mephenytoin/metabolism , Nicergoline/pharmacology , Phenotype , Vasodilator Agents/pharmacology
10.
J Antimicrob Chemother ; 37(6): 1111-9, 1996 Jun.
Article in English | MEDLINE | ID: mdl-8836814

ABSTRACT

Important species differences have been reported concerning the induction properties of rifampicin towards enzymes of the P-450 superfamily. Mice, rabbits and humans are far more responsive than rats and guinea pigs. In the present study a strong induction of cytochrome P-450 3A-dependent enzyme activities was observed in female rat liver microsomes after high dose treatment (> or = 250 mg/kg/day for 9 days) with rifampicin, resulting in an up to 30-fold enhanced hydroxylation rate of testosterone in the 2 beta-, 6 beta- and 15 beta-position in vitro. Other cytochrome P-450 isozyme-selective reactions were not, or only marginally, affected. A steep increase in cytochrome P-450 3A activity on a moderate elevation of the dose administered, together with the previously observed lack of efficient induction with doses below 200 mg/kg/day demonstrated that there is a threshold in enzyme induction by rifampicin. For rifabutin such a threshold was not apparent. Induction by rifabutin showed an isoenzyme-selectivity profile similar to that produced by rifampicin, but the maximally achievable induction of cytochrome P-450 3A by rifabutin was about two-fold lower compared with rifampicin. Rifampicin and rifabutin enhanced the glucuronidation of 1-naphthol, 4-hydroxybiphenyl and beta-estradiol by a factor of two to three. The potential implications of the enzyme induction by rifampicin derivatives in terms of possible drug-drug interactions are discussed.


Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Glucuronosyltransferase/metabolism , Liver/enzymology , Rifabutin/pharmacology , Rifampin/pharmacology , Animals , Antibiotics, Antitubercular/pharmacology , Cytochrome P-450 Enzyme System/drug effects , Dose-Response Relationship, Drug , Female , Glucuronosyltransferase/drug effects , Liver/drug effects , Rats , Rats, Wistar , Rifabutin/toxicity , Rifampin/toxicity , Testosterone/metabolism
11.
Pharmacol Res ; 32(4): 177-87, 1995 Oct.
Article in English | MEDLINE | ID: mdl-8866833

ABSTRACT

Rifabutin, a rifamycin derivative like rifampicin, has been registered for the treatment of pulmonary tuberculosis and for the prophylaxis and treatment of MAC in patients with AIDS. Rifabutin induces cytochrome P-450 3A4. The effect of rifabutin on the pharmacokinetics and metabolism of drugs administered concomitantly to humans (isoniazid, ethambutol, zidovudine, didanosine, delavirdine, fluconazole, itraconazole, methadone, clarithromycin, theophylline and cyclosporin) has been reviewed.


Subject(s)
Rifabutin/pharmacokinetics , Acquired Immunodeficiency Syndrome/drug therapy , Humans , Isoniazid/pharmacology , Tuberculosis/drug therapy
12.
J Pharm Pharmacol ; 46(10): 814-9, 1994 Oct.
Article in English | MEDLINE | ID: mdl-7699569

ABSTRACT

The effects of the potent anticonvulsant FCE 26743 ((S)-2-(4-3-fluorobenzyloxy)benzylamino)propionamide) on monoamine oxidase (MAO) activity were measured in-vitro and ex-vivo using rat tissue homogenates. In-vitro, FCE 26743 showed potent and selective inhibitory properties towards liver MAO-B, with IC50 values about 10(-7) M for MAO-B and higher than 10(-5) M for MAO-A. When determined ex-vivo in brain, the ED50 value for the inhibition of MAO-B was 1.1 mg kg-1 (p.o.) 1 h post-dosing, whereas MAO-A remained virtually unaffected after administration of 60 mg kg-1. Similar effects were seen in liver. Following oral administration of 5 mg kg-1 FCE 26743 to rats, brain MAO-B inhibition was 79% after 1 h and 13% after 24 h, indicating that FCE 26743 behaves as a short-acting MAO-B inhibitor. The ability of FCE 26743 to act as a MAO substrate was assessed in mice by measuring the urinary excretion of alaninamide, a potential metabolite of FCE 26743 which would result from the action of MAO. No alaninamide was detectable in the 0-8 h urines after administration of a 119 mg kg-1 dose, suggesting that FCE 26743 is not, or only to a small degree, a substrate of MAO. The effects of FCE 26743 on cytochrome P450 enzymes involved in testosterone hydroxylation were determined in rats after repeated administration. No induction of the cytochrome P450 system was noted.


Subject(s)
Alanine/analogs & derivatives , Anticonvulsants/pharmacology , Benzylamines/pharmacology , Cytochrome P-450 Enzyme System/physiology , Monoamine Oxidase Inhibitors/pharmacology , Testosterone/metabolism , Alanine/pharmacology , Animals , Brain/metabolism , Cytochrome P-450 Enzyme System/drug effects , Dose-Response Relationship, Drug , Hydroxylation , In Vitro Techniques , Liver/metabolism , Male , Mice , Mice, Inbred Strains , Rats , Rats, Sprague-Dawley
14.
J Chromatogr ; 620(2): 225-31, 1993 Oct 29.
Article in English | MEDLINE | ID: mdl-8300790

ABSTRACT

A sensitive and selective high-performance liquid chromatographic method for the determination of 6-methylen-androsta-1,4-diene-3,17-dione (exemestane) and its 17-dihydro metabolite in human plasma has been developed. The analytes and internal standard (Norgestrel) were extracted from plasma samples with a methylene chloride-iso-octane mixture; the organic phase was dried and the residue was reconstituted with an acetonitrile-water mixture, then analyzed by reversed-phase liquid chromatography. Quantification was achieved by ultraviolet detection of the eluate. The linearity, precision and accuracy of the method were evaluated. No interference from the constituents of human blank plasma was observed. The lower limit of quantification was 10 ng/ml plasma. The suitability of the method for in vivo samples was checked by analysis of plasma samples drawn from healthy male volunteers who had received a 200-mg single oral dose of the test compound.


Subject(s)
Androstadienes/blood , Aromatase Inhibitors , Chromatography, High Pressure Liquid/methods , Humans , Male , Reproducibility of Results , Spectrophotometry, Ultraviolet
15.
Cancer Res ; 52(21): 5933-9, 1992 Nov 01.
Article in English | MEDLINE | ID: mdl-1394219

ABSTRACT

Aromatase inhibitors are a useful therapeutic option in the management of endocrine-dependent advanced breast cancer. A single-dose administration of exemestane (FCE 24304; 6-methylenandrosta-1,4-diene-3,17-dione), a new irreversible aromatase inhibitor, was investigated in 29 healthy postmenopausal female volunteers. The compound, given at p.o. doses of 0.5, 5, 12.5, 25, 50, 200, 400, and 800 mg (n = 3-4), was found to be a well tolerated, potent, long-lasting, and specific inhibitor of estrogen biosynthesis. The minimal dose which produced the maximum suppression of plasma estrogens was 25 mg, reducing plasma estrone, estradiol, and estrone sulfate to 35, 28, and 39% of basal values, respectively. This maximum suppression, observed at 3 days, persisted for at least 5 days after administration of a single dose. However, there was no interference on cortisol, aldosterone, 17-hydroxyprogesterone, or dehydroepiandrostenedione sulfate plasma levels. Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively. Plasma concentrations declined rapidly and fell under the detection limit (10 ng/ml) at 4 (50 mg) or 24 h (200 and 400 mg). No clinically significant adverse events which could be attributed to the drug were reported. Apart from transient eosinophilia in 3 patients, all biochemical and hematological laboratory parameters were within 1.25-fold of the normal ranges.


Subject(s)
Androstadienes/pharmacology , Aromatase Inhibitors , Menopause/blood , Aged , Androstadienes/administration & dosage , Androstadienes/adverse effects , Androstadienes/pharmacokinetics , Androstenedione/blood , Dehydroepiandrosterone/blood , Estrogens/blood , Estrogens/urine , Female , Follicle Stimulating Hormone/blood , Headache/chemically induced , Humans , Luteinizing Hormone/blood , Menopause/urine , Middle Aged , Testosterone/blood
16.
J Chromatogr ; 578(2): 309-15, 1992 Jul 24.
Article in English | MEDLINE | ID: mdl-1400812

ABSTRACT

A sensitive and selective high-performance liquid chromatographic method for the determination of 3'-deamino-3'-[2(S)-methoxy-4-morpholinyl]doxorubicin and its possible 13-dihydro metabolite in human plasma has been developed. The plasma samples were buffered and the drugs and internal standard (doxorubicin) were extracted with diethyl ether-n-butanol, back-extracted into 0.3 M phosphoric acid, then analysed by reversed-phase liquid chromatography. Quantitation was achieved by fluorescence detection of the eluate. The linearity, precision and accuracy of the method were evaluated. No interference from blank plasma sample was observed. The suitability of the method for in vivo samples was checked by analysis of plasma samples drawn from female rats that had received repeated intravenous doses of the test compound.


Subject(s)
Antibiotics, Antineoplastic/blood , Doxorubicin/analogs & derivatives , Animals , Chromatography, High Pressure Liquid , Doxorubicin/blood , Female , Humans , Rats , Reproducibility of Results , Spectrometry, Fluorescence
17.
Drug Metabol Drug Interact ; 10(3): 199-211, 1992.
Article in English | MEDLINE | ID: mdl-1424641

ABSTRACT

After oral administration of [3H]cabergoline to man at a single nominal dose of 0.6 mg/subject radioactivity is mainly eliminated by the faecal route (72% of the dose after 10 days). Urine contains 18% of the dose after the same period. The unchanged drug and metabolites present in urine were identified by comparison with reference compounds and quantified by radio-TLC analysis. Cabergoline is extensively metabolized. Unchanged drug in 0-24 h urine represents less than 14% of urinary radioactivity, reaching 20% in 0-96 h urine. The acid derivative FCE 21589 is the main metabolite, amounting to 38% and 30% of the urinary radioactivity in 0-24 h and 0-96 h urine, respectively. The amide derivative FCE 21590 appears to be present in only a small amount, accounting for no more than 4% of the urinary radioactivity in the urine of the first 24 hours after administration and increasing to about 8% in the 0-96 h urine.


Subject(s)
Ergolines/pharmacokinetics , Prolactin/metabolism , Adult , Cabergoline , Drug Stability , Ergolines/urine , Feces/chemistry , Humans , Male , Scintillation Counting , Tritium
18.
Drug Metabol Drug Interact ; 10(3): 185-97, 1992.
Article in English | MEDLINE | ID: mdl-1424640

ABSTRACT

[3H]-FCE 22716 and [3H]-FCE 24220 were given both orally and intravenously to the rat. Radioactivity was mainly eliminated by the faecal route after oral administration in both cases. After intravenous administration, renal excretion was twice the faecal one in the case of FCE 22716, whereas for FCE 24220 the two routes were equal. In urine FCE 22716 was eliminated almost completely unchanged after both oral and intravenous administration. FCE 24220 was extensively reduced to FCE 22716 after oral administration, whereas after intravenous treatment, this reduction, although important, was not complete.


Subject(s)
Antihypertensive Agents/pharmacokinetics , Ergolines/pharmacokinetics , Hydantoins/pharmacokinetics , Administration, Oral , Animals , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/urine , Biotransformation , Drug Stability , Ergolines/administration & dosage , Ergolines/urine , Feces/chemistry , Hydantoins/administration & dosage , Hydantoins/urine , Injections, Intravenous , Male , Molecular Structure , Rats , Rats, Sprague-Dawley , Tritium
19.
J Pharm Sci ; 80(12): 1130-2, 1991 Dec.
Article in English | MEDLINE | ID: mdl-1839998

ABSTRACT

Medroxyprogesterone acetate (MPA) is widely used in the hormonal therapy of breast cancer. So far, oral formulations of MPA commercially available present a very low bioavailability, with a less than 10% extent of oral absorption. A new oral preparation of MPA has been recently developed. Based on a pilot study, an open, randomized, crossover trial has been performed on 22 breast and endometrial cancer patients to evaluate the relative bioavailability of this new oral formulation (200-mg sachet, twice daily) as compared with a standard formulation (Farlutal, 500-mg tablet, twice daily). The bioavailability evaluation was mainly based on the area under the curve measured between two administrations at steady state, after 15 days of continuous therapy. Wide interpatient variability of MPA plasma levels after oral MPA administration was confirmed. The MPA plasma levels were higher in patients treated with the new formulation than in patients treated with Farlutal. The relative bioavailability of the new preparation was 3.5 times higher than that of the standard. This new formulation represents a great improvement in the extent of oral absorption of MPA and could lead to better management of hormone-responsive tumors by hormonal therapy.


Subject(s)
Antineoplastic Agents/pharmacokinetics , Breast Neoplasms/metabolism , Medroxyprogesterone/analogs & derivatives , Uterine Neoplasms/metabolism , Administration, Oral , Adult , Aged , Analysis of Variance , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Biological Availability , Female , Humans , Medroxyprogesterone/administration & dosage , Medroxyprogesterone/adverse effects , Medroxyprogesterone/pharmacokinetics , Medroxyprogesterone Acetate , Middle Aged
20.
J Neural Transm Gen Sect ; 86(3): 191-203, 1991.
Article in English | MEDLINE | ID: mdl-1777213

ABSTRACT

Concentrations of the sulfur-containing amino acids methionine, homocysteic acid, cysteic acid and taurine were measured in brain structures of young and old Wistar rats in an attempt to establish a possible link between the increase in oxidative stress with ageing and changes in tissue levels of these amino acids. Contrary to data reported by others, in all brain structures of young and old rats homocysteic acid levels could not be quantified. Compared with young rats, in old animals taurine and methionine concentrations significantly decreased in striatum and cortex; decreased taurine levels were also found in nucleus accumbens and cerebellum and lower concentrations of methionine were found in midbrain, hippocampus and pons-medulla. Cysteic acid levels either did not change or significantly increased in cortex and hippocampus. These results are discussed taking into account the biosynthesis of sulfur-containing amino acids in rat brain and the decrease in glutathione in relation to oxidative stress with ageing. Changes in aspartic acid, glutamic acid, serine, glutamine, glycine and GABA concentrations with ageing were also determined in the same brain structures and were in good agreement with those previously reported (Strolin Benedetti et al., 1990 a, b).


Subject(s)
Aging/physiology , Amino Acids, Sulfur/metabolism , Brain Chemistry/physiology , Animals , Male , Rats , Rats, Inbred Strains , gamma-Aminobutyric Acid/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...